Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies.

Current drug targets - 1 Oct 2009

Chiuri Vincenzo Emanuele, Silvestris Nicola, Lorusso Vito, Tinelli Andrea

Abstract excerpt

Docetaxel is a chemotherapeutic drug which has recently demonstrated high efficacy in the treatment of a wide variety of tumors. Numerous novel targeted drugs are being introduced in preclinical and clinical practice, aiming to directly inhibit pathways responsible for the maintenance of transformed and immortalized phenotypes of cancer cells. Herein we reported the efficacy and safety results of the most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biological Products

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Docetaxel

Share to Drug Delivery Systems

Share to Neoplasms

Share to Phenotype

Share to Taxoids

Source

Identifiers

PMID: 19663766
DOI: 10.2174/138945009789578007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of the combination of docetaxel (Taxotere) with targeted therapies in the treatment of solid malignancies.PMID 19663766Read ↗

Combined Treatment with Stattic and Docetaxel Alters the Bax/Bcl-2 Gene Expression Ratio in Human Prostate Cancer CellsSemantic proximity Read ↗

A phase I study of AZD8186 in combination with docetaxel in patients with PTEN-mutated or PIK3CB-mutated advanced solid tumors.Semantic proximity Read ↗

Key genes and molecular mechanisms related to Paclitaxel ResistanceSemantic proximity Read ↗

Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.Semantic proximity Read ↗

Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.Semantic proximity Read ↗

Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRAS.Semantic proximity Read ↗

An overview on anti-tubulin agents for the treatment of lymphoma patientsSemantic proximity Read ↗

Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation TaxanesSemantic proximity Read ↗

Rationale and clinical use of multitargeting anticancer agentsSemantic proximity Read ↗

Molecular mechanisms of docetaxel resistance in prostate cancerSemantic proximity Read ↗

Telling Cells How to Die: Docetaxel Therapy in Cancer Cell LinesSemantic proximity Read ↗

Docetaxel induces cell death through mitotic catastrophe in human breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.